Background Nevirapine given once-daily for the fi rst 6, 14, or 28 weeks of life to infants exposed to HIV-1 via breastfeeding reduces transmission through this route compared with single-dose nevirapine at birth or neonatally. We aimed to assess incremental safety and effi cacy of extension of such prophylaxis to 6 months.
Introduction
Breastfeeding in sub-Saharan Africa provides vital nutrition for infants between birth and 24 months of age and provides protection against respiratory and diarrhoeal illnesses, leading to improved overall survival. However, breastfeeding up to 24 months of age in infants exposed to HIV can account for 30-40% of all mother-to-child transmission.
1,2 Therefore, although prophylactic antepartum and intrapartum antiretroviral regimens can substantially reduce in utero and intrapartum mother-tochild transmission, these substantial gains are lost in breastfeeding populations in whom infants have continued exposure to HIV-1 from breast milk. 3, 4 Extended regimens of 6, 14, and 28 weeks' nevirapine are eff ective in infants for reduction of postnatal HIV-1 transmission, as is 6 months of postnatal triple-drug prophylaxis for mothers. [5] [6] [7] [8] However, strategies for prevention of mother-to-child transmission (PMTCT) require extensive, coordinated services and postnatal prevention regimens can be costly. Moreover, in many settings infants exposed to HIV-1 are lost to follow-up after the fi rst postpartum visit. 9 Consequently, postnatal prophy lactic antiretroviral regimens for PMTCT have been diffi cult to implement in many low-income settings, despite WHO guidelines recommending extended breastf eeding for infants exposed to HIV-1 until the age of 12 months together with antiretroviral prophylaxis for the mother or infant for the duration of breast feeding. 10, 11 Implementation of the complete cascade of PMTCT services, including routine HIV screening of pregnant women, provision of antiretroviral interventions during pregnancy, labour, and delivery, and during breastfeeding, and linkage to long-term care and treatment services for HIV infected mothers in low-income settings is crucial to substantially reduce global perinatal HIV-1 infection. 12 Implicit in such eff orts is an assessment of the absolute eff ectiveness of every step of the PMTCT cascade, including antiretroviral inter ventions during breastfeeding. The duration of published infant prophylaxis regimens ranges from several weeks to several months, and the infrastructure investments needed for every regimen can vary widely, which might aff ect the feasibility of provision of these interventions. We aimed to assess the incremental effi cacy and safety of extension of oncedaily nevirapine until the age of 6 months in African infants exposed to HIV-1 during breastfeeding who had already received 6 weeks of once-daily nevirapine.
Methods

Study design and participants
HPTN 046 was a phase 3, randomised, double-blind, placebo-controlled trial that assessed the effi cacy and safety of extension of once-daily nevirapine to 6 months of age or until cessation of breastfeeding (whichever came fi rst) for prevention of transmission in HIV-1-exposed breastfeeding infants who had received nevirapine prophylaxis until the age of 6 weeks.
Women were recruited from antenatal clinics in Durban in South Africa, Dar es Salaam in Tanzania, Kampala in Uganda, and Chitungwiza in Zimbabwe, where HIV-1 testing, counselling, and the local standard of care antiretroviral regimen for PMTCT were provided. All women provided written informed consent. Eligible women and infants were enrolled within 7 days of delivery. Primary eligibility criteria included maternal age (≥18 years), infant HIV-1 DNA PCR negative from a specimen obtained within 7 days of birth, and birthweight of 2000 g or more. We excluded women and infants if either had a serious medical disorder that would interfere with study participation. Women receiving antiretroviral drugs for HIV-1 treatment or for PMTCT were eligible. Infant study visits were undertaken within 7 days postpartum, at 2, 5, 6, and 8 weeks, and at 3, 6, 9, 12, and 18 months. Infants who developed HIV-1 infections were taken off study drug and referred for additional care and treatment.
The study protocol was approved by at least one local ethics review committee affi liated with every study site, by committees affi liated with US collaborating institutions, and by other local regulatory bodies where applicable.
Randomisation and masking
All enrolled infants received once-daily open-label nevirapine (10 mg/mL oral suspension) for the fi rst 6 weeks of life. After such treatment (at age 6-8 weeks), we randomly allocated eligible infants in a one-to-one ratio to receive extended nevirapine (treatment group) or placebo (control group) according to computer-generated permutated block algorithms by site with random block sizes. Because maternal receipt of anti retroviral drugs can aff ect postnatal transmission, infants were stratifi ed by maternal antiretroviral treatment status at randomisation. 8, 13 Infants had to be HIV-1 DNA PCR negative on a specimen obtained within 21 days before randomisation and still breastfeeding, with the mother's intent to continue breastfeeding. An independent contractor in the USA provided identical, sealed, individual study drug kits, which were prepared and labelled centrally according to the random allocation assignment generated by the HPTN Statistical and Data Management Center (Seattle, WA, USA). These kits were sent to the study sites for sequential assignment to infants as they were randomised. Study staff and participants were masked to the study drug (nevirapine or placebo) assignment.
Procedures
Women gave study drug to their children with calibrated oral syringes. Randomly allocated infants started masked study drug and continued a once-daily dosing regimen until 6 months of age or until cessation of breastfeeding, whichever came fi rst. The nevirapine dose was increased with age, ranging from 20 mg once-daily after 6-8 weeks of age to 28 mg once-daily after 5-6 months of age. Women were counselled to exclusively breastfeed for 6 months.
The primary effi cacy endpoint was HIV-1 infection at age 6 months in infants who were uninfected at age 6 weeks in each study group. Primary safety endpoints were frequency and severity of adverse reactions in randomly allocated infants until age 6 months in each group for all infants who received at least one dose of study intervention. Secondary endpoints included HIV-1-free survival, relative rates of HIV-1 infection, and infant survival rates (mortality irrespective of HIV-1 infection) in the two study groups.
We tested infants for HIV-1 infection at 3, 6, 9, 12, and 18 months. Infant blood was stored at randomisation and tested retrospectively in those who had HIV-1-infection at the 3 month visit. Infants identifi ed as HIV-1-infected at 6 weeks were excluded from analysis of primary and secondary endpoints. We defi ned HIV-1 infection as two separate peripheral blood specimens drawn on diff erent days that were positive by HIV-1 DNA PCR. HIV-1 DNA was measured at site laboratories with the Roche AMPLICOR HIV-1 DNA test, version 1. and fever in infants. The three scales were adapted from diff erent sources; the rash grading scale was adapted from standard NIAID/DAIDS rash grading; the malnutrition scale was adapted from the WHO defi nitions associated with malnutrition; and the fever scale was based on the standard NIAID/DAIDS grading, with adjustment for axillary measurement. We reported all adverse events (serious and non-serious) up to age 8 months (8 weeks after maximum study drug dosing); thereafter, only serious adverse events were reported. We assessed breastfeeding status at every infant visit and cessation was established by maternal report of last date of infant breastmilk exposure. All infants had reached age 6 months (for ascertainment of the primary study endpoints) by July, 2010, and 12 months of age by January, 2011. Our present analyses are for data obtained by the 12 month visit. Follow-up of infants is continuing to 18 months of age for further assessment of secondary endpoints.
Statistical analysis
On the basis of results from the Six Week Extended-Dose Nevirapine (SWEN) study, 5 we assumed that the overall rate of HIV-1 infection in the placebo group would be about 2·6% at age 6 weeks and about 6·7% at age 6 months, giving a cumulative infection rate of 4·2% between these ages in the control group. We estimated that 1500 mother-infant pairs would provide 90% power to detect a reduction in HIV-1 infection from 4·2% to 1·4% at age 6 months with a Pearson χ² test statistic and a one-sided false positive error rate of 0·025.
We summarised baseline characteristics with means and proportions. We calculated rates of cumulative infection, death, and HIV-1-free survival by randomisation group at 6, 9, and 12 months with the Kaplan-Meier method, and 95% CIs with Greenwood's formula. We compared cumulative rates with the Z statistic. Time of HIV-1 infection was defi ned as the midpoint between the last negative and the fi rst positive HIV-1 test. For the cumulative-infection analysis, infants with no positive tests were censored at the time of last negative test. For HIV-1-free survival, the event time was the minimum of the infection time and the death time with censoring at the last negative test if no positive test or death was reported. We also created Kaplan-Meier curves of time to breastfeeding cessation, with comparisons between groups done with the log-rank test. Reported p values and CIs have not been adjusted for interim analyses or multiple comparisons. All statistical analyses were performed using SAS version 9.0 for UNIX.
This study is registered with ClinicalTrials.gov, number NCT00074412.
Role of the funding source
The sponsor (US National Institutes of Health) participated in the design and oversight of the study, interpretation of the results, and preparation of the manuscript. The sponsor also provided for an inde pendent data and safety monitoring board to review the trial every 6 months. Members of the writing team had full access to the study data. The protocol chair, cochairs, and sponsor representatives had fi nal responsibility for the decision to submit for publication.
Results
We randomly allocated 1527 infants aged 6 Trial profi le *Only main cause is listed. †Two fi rst-born twins not eligible, one congenital heart defect, one mother in accident, two poor adherence to study procedures, and one mother could not dose competently.
characteristics of the infants and their mothers did not diff er (table 1) . At randomisation, 444 (30%) of 1505 mothers overall were on highly active antiretroviral therapy for their own health, increasing to 227 (31%) of 725 in the extended nevirapine group and 231 (32%) of 725 in the placebo group at 6 months. Median maternal CD4+ lymphocyte counts at randomisation at 6 weeks' postpartum were 528 cells per μL in the extended nevirapine group and 557 cells per μL in the placebo group. Breastfeeding status was assessed at each study visit; more than 95% of infants in both groups were no longer breastfed by the 9 month study visit. Time to breastmilk cessation diff ered by study site (log-rank p<0·0001; data not shown) but not by study group (p=0·71; fi gure 2).
Study drug adherence was measured as the proportion of infants who were reported to have received all scheduled doses since their last follow-up visit. Such adherence was 88-96% up to age 6 months and did not diff er between sites or study groups. 1446 (97%) of 1496 infants expected to remain in the study did so at 6 months and 1180 (94%) of 1259 infants expected to remain in the study did so at 12 months; these proportions did not diff er between study sites or groups. Table 2 shows rates of HIV-1 infection and death by study group. From Kaplan-Meier analysis, 1·1% (95% CI 0·3-1·8) of infants developed postnatal HIV-1 infection between ages 6 weeks and 6 months in the extended nevirapine group compared with 2·4% (1·3-3·6) of infants in the placebo group (diff er ence 1·3%, 95% CI 0-2·6; p=0·049), equating to a 54% reduction in HIV-1 transmission (fi gure 3). Study interventions stopped at age 6 months. Diff erences between study groups were no longer signifi cant at 9 months and 12 months of age.
When stratifi ed by mothers who had highly active antiretroviral therapy at randomisation, infants born to these mothers had low rates of HIV-1 infection, which did not diff er by study group at any age, whereas infants born to mothers who were not on such therapy had signifi cantly lower rates of HIV-1 infection at 6 months with extended nevirapine (1·3%) compared with placebo (3·4%; p=0·027), but not at 9 or 12 months (table 2) . Because WHO recommends treatment for women with low CD4 cell counts (ie, <350 cells per μL), we did a post-hoc analysis that assessed infection rates in infants born to mothers with high CD4 cell counts (≥350 cells per μL) who were not receiving highly active antiretroviral therapy at randomisation. In this subgroup, infants randomly allocated to the extended nevirapine group had a 6 month HIV-1 infection rate of 0·7%, which is much the same as that reported in infants of mothers on such therapy, compared with 2·8% for infants in the placebo group (p=0·014; diff erence 2·1%, 95% CI 0·4-3·9), for a 75% reduction in HIV-1 transmission. This diff erence continued to be signifi cant at 9 months but not at 12 months. However, rates of HIV-1 infection did not diff er in infants of women not receiving highly Median 3100 (2800-3400) 3100 (2800-3400) Data are n, median (IQR), or n (%). HAART=highly active antiretroviral therapy. Figure 2: Kaplan-Meier analysis of breastfeeding duration, by study group active antiretroviral therapy who had low CD4 cell counts. Overall survival and HIV-1-free survival did not diff er in infants between study groups at 6, 9, or 12 months (table 2) . However, most infant deaths occurred after age 6 months and cessation of breastfeeding.
Overall, 1259 (83%) of 1519 infants from both groups had adverse events (table 3) . 125 (16%) of 758 infants given extended nevirapine and 116 (15%) of 761 controls had serious adverse events. Of 1519 infants who received at least one dose of nevirapine or placebo, the most common serious adverse events were gastroenteritis in 81 (5%) infants, pneumonia or bronchopneumonia in 73 (5%) infants, malaria in 54 (4%) infants, and kwashi orkor in 12 (1%) infants, with no signifi cant diff erence between study groups. In the 46 infant deaths reported by age 12 months (20 in the extended nevirapine group and 26 in the placebo group), the most frequent associated adverse events were gastroenteritis (11 infants) and pneumonia or broncho pneumonia (10 infants). Prevalence of laboratory abnor malities or rash did not diff er between study groups (table 3).
Discussion
After 6 weeks of treatment with once-daily nevirapine, continued use of nevirapine to age 6 months in uninfected infants of breastfeeding mothers with HIV-1 is safe, and results in a greater than 50% reduction in mother-to-child transmission from breastfeeding compared with placebo. No other study has directly assessed the incre mental benefi t of extension of nevirapine from age 6 weeks until 6 months to establish whether the extended period is Data are cumulative number of events/number at risk unless otherwise stated. HAART=highly active antiretroviral therapy. *Two-sided p value for Z statistic of the diff erence in probabilities. †Cumulative rates at 6, 9, and 12 months calculated with Kaplan-Meier methods. Table 2 : Cumulative incidence of HIV-1 infection or death in infants uninfected at age 6 weeks more effi cacious and whether there are increased safety issues associated with long-term treatment with nevirapine (panel). Our results, in addition to the published data for the effi cacy of 6, 14, and 28 weeks of infant nevirapine, show the consistent benefi t and safety of nevirapine for prevention of HIV-1 transmission via breastfeeding in the fi rst 6 months of life. [5] [6] [7] We also show that, once prophylaxis ends, trans mission risk returns at rates much the same as that reported without prophylaxis. These fi ndings provide further evidence for the safety and effi cacy of infant nevirapine prophylaxis for 6 months of exclusive breast feeding, as is recommended by the WHO. Furthermore, these results provide a proof of principle for the WHO recommendations to continue infant antiretroviral prophylaxis throughout the period of breastfeeding, whether it lasts 6 months or longer.
The eff ect of the 6 month nevirapine regimen described in our study on reduction of HIV-1 breastfeeding transmission was especially striking in infants of women whose CD4+ cell counts were 350 cells per μL or more and who therefore would not qualify for highly active antiretroviral therapy for their own health according to present WHO criteria. 11 In this population of motherinfant pairs, there was an overall four-fold decrease in HIV-1 breastfeeding transmission compared with transmission in infants who received placebo from age 6 weeks to 6 months (0·7% nevirapine vs 2·8% placebo). HIV-1 infection rates during extended nevirapine prophylaxis in infants born to women with high CD4 cell counts who were not receiving highly active antiretroviral therapy (0·7%) were much the same as infection rates reported in infants born to such women receiving this therapy (0·5%).
The importance of identifi cation of and provision of therapy to women with low CD4 cell counts is shown by the high postnatal HIV-1 transmission rates reported in infants born to women not on highly active antiretroviral therapy with low CD4 cell counts (<350 cells per μL) irrespective of study group. In a study in Zambia, 18 88% of perinatal and postnatal HIV-1 infections occurred in women who met the WHO criteria for receipt of treatment. Provision of highly active antiretroviral therapy seems to be very eff ective for reduction of postnatal infection in this population. Moreover, our study shows that extended nevirapine off ers no additional benefi t compared with 6 weeks of nevirapine in infants born to women receiving highly active antiretroviral therapy, supporting the present recommendation by the WHO for only 6 weeks of infant prophylaxis for infants of women on such treatement.
Previous studies suggested effi cacy of other extended nevirapine regimens in infants for prevention of breastfeeding HIV-1 transmission. The SWEN study 5 showed that once-daily infant nevirapine for 6 weeks resulted in a 53% reduction in postnatal HIV-1 infection at age 6 weeks compared with single-dose nevirapine (HIV-1 infection incidence of 2·5% vs 5·3%, respectively). The PEPI-Malawi study 6, 17 showed that once-daily infant nevirapine for 14 weeks resulted in a 69% reduction in the risk of postnatal HIV-1 infection at age 14 weeks compared with single-dose nevirapine and 1 week of infant zidovudine (2·6% vs 8·5%, respectively); however, follow-up to 24 months suggested continued transmission after cessation of nevirapine prophylaxis. The Breastfeeding and Nutrition study, 7 which was undertaken in Malawi in infants born to mothers with CD4 cell counts of more than 250 cells per μL, showed that postnatal HIV-1 infection in infants uninfected at age 2 weeks was signifi cantly reduced with 6 months of either maternal triple antiretroviral prophylaxis or extended infant nevirapine compared with single-dose nevirapine (2·9% for triple prophylaxis, 1·7% for extended nevirapine, and 5·7% for single-dose nevirapine); however, there was not a signifi cant diff erence between the extended maternal and infant regimens. Effi cacy of the infant nevirapine regimen in the Breastfeeding and Nutrition study 7 was 70%, which is much the same as that reported with extended nevirapine in infants born to mothers with high CD4 cell counts (≥350 cells per μL) not receiving highly active antiretroviral therapy in our study (6-month HIV-1 infection rate of 1·1% with extended nevirapine vs 2·4% with placebo in infants receiving nevirapine up to 6 weeks of age). Therefore, the superiority of 6 months versus 6 weeks of nevirapine showed in HPTN 046 is consistent with the relative reductions in transmission reported in each of these studies.
Infant mortality did not diff er signifi cantly between study groups in our study. However, most infant deaths occurred after age 6 months and nearly all infants stopped breastfeeding by 6-9 months of age. Various studies have shown increased rates of infant mortality with early breastfeeding cessation before the age of 12 months, especially in infants born to mothers with low severity HIV-1 disease.
19-21
Our analyses did not adjust for multiple statistical tests, thus increasing the risk of false-positive fi ndings. However, because of the higher than expected rate of maternal highly active antiretroviral therapy use, we reported fewer infant infections than expected, which reduced our power to detect diff erences in HIV transmission risks between groups.
The major obstacles to PMTCT are the following factors: identifi cation of pregnant women with HIV-1 infection; 22 identifi cation of and provision of highly active antiretroviral therapy to those women who need treatment for their own health (ie, those who have highest HIV-1 transmission risk); and provision of antiretroviral prophylaxis for those women who do not yet qualify for treatment based on WHO guidelines or for their infants. An analysis 23 of the use of maternal triple antiretroviral prophylaxis compared with infant nevirapine prophylaxis for PMTCT in women who do not need therapy for their own health suggested that both interventions reduced the risk of transmission but that the cost of maternal prophylaxis was substantially greater than was the cost of infant nevirapine. Our study suggests the safety and incremental effi cacy of extension of nevirapine to 6 months for prevention of postnatal HIV-1 infection in infants of women who do not need therapy and also shows the eff ectiveness of highly active antiretroviral therapy in reduction of mother-to-child transmission in infants born to women with low CD4+ cell counts needing therapy. Global elimination of paediatric HIV-1 will require a multifaceted approach including primary prevention in women of childbearing age; prioritisation of eff orts to identify and treat those pregnant women with HIV-1 who need therapy for their own health (which will benefi t both the woman and prevent transmission to her infant); and provision of an eff ective prophylaxis regimen such as extended nevira pine to infants of women who do not need therapy to permit safe, long-term breastfeeding.
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